Tarsus Pharmaceuticals (TARS) Moves 7.5% Higher: Will This Strength Last?Zacks Investment Research • 07/03/26
Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million AmericansGlobeNewsWire • 05/14/26
Tarsus Pharmaceuticals, Inc. (TARS) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking Alpha • 05/13/26
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Beats Revenue EstimatesZacks Investment Research • 05/06/26
Tarsus Reports First Quarter 2026 Financial Results and Recent Business AchievementsGlobeNewsWire • 05/06/26
Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026GlobeNewsWire • 04/29/26
Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme DiseaseGlobeNewsWire • 03/31/26
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to TarsusGlobeNewsWire • 03/23/26
Tarsus Pharmaceuticals, Inc. (TARS) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptSeeking Alpha • 03/11/26
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Beats Revenue EstimatesZacks Investment Research • 02/24/26
Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of DirectorsGlobeNewsWire • 02/18/26
Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026GlobeNewsWire • 02/17/26
Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 02/17/26
Down 16.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Tarsus Pharmaceuticals (TARS)Zacks Investment Research • 01/26/26